UA101362C2 - Protein tyrosine kinase activity inhibitors - Google Patents

Protein tyrosine kinase activity inhibitors

Info

Publication number
UA101362C2
UA101362C2 UAA201011785A UAA201011785A UA101362C2 UA 101362 C2 UA101362 C2 UA 101362C2 UA A201011785 A UAA201011785 A UA A201011785A UA A201011785 A UAA201011785 A UA A201011785A UA 101362 C2 UA101362 C2 UA 101362C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
activity inhibitors
compounds
Prior art date
Application number
UAA201011785A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мишель Маннион
Стефан Раппель
Стефен Вильям Кларидж
Фредерик Годетте
Лиже Зан
Любомир ИСАКОВИЧ
Оскар Марио СААВЕДРА
Тесююки Уно
Масаши КИШИДА
Аркадий Вайсбург
Original Assignee
Метилген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метилген Инк. filed Critical Метилген Инк.
Publication of UA101362C2 publication Critical patent/UA101362C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Это изобретение касается соединений, которые ингибируют активность протеинтирозинкиназ. В частности, изобретение касается соединений, которые ингибируют активность протеинтирозинкиназ рецепторов факторов роста, который приводит к ингибированию сигнализации рецепторов, например ингибирования сигнализации рецепторов VEGF.Изобретение также предлагает соединения, композиции и способы лечения болезней и состояний разрастания клеток и офтальмологических болезней, расстройств и состояний.
UAA201011785A 2008-03-05 2009-02-27 Protein tyrosine kinase activity inhibitors UA101362C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3400508P 2008-03-05 2008-03-05
PCT/CA2009/000228 WO2009109035A1 (en) 2008-03-05 2009-02-27 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
UA101362C2 true UA101362C2 (en) 2013-03-25

Family

ID=41055503

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201013462A UA100262C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы
UAA201011785A UA101362C2 (en) 2008-03-05 2009-02-27 Protein tyrosine kinase activity inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201013462A UA100262C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы

Country Status (19)

Country Link
US (3) US8729268B2 (ru)
EP (2) EP2262815A4 (ru)
JP (2) JP2011513339A (ru)
KR (2) KR20100137495A (ru)
CN (2) CN102015723B (ru)
AR (2) AR070539A1 (ru)
AU (2) AU2009221583B2 (ru)
BR (2) BRPI0908573A2 (ru)
CA (2) CA2717816A1 (ru)
CO (1) CO6290684A2 (ru)
IL (2) IL207946A0 (ru)
MX (1) MX2010009729A (ru)
NZ (2) NZ588355A (ru)
RU (2) RU2533827C2 (ru)
SG (1) SG182146A1 (ru)
TW (2) TW200940549A (ru)
UA (2) UA100262C2 (ru)
WO (1) WO2009109035A1 (ru)
ZA (2) ZA201005868B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
US8614234B2 (en) * 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators
PH12012502073A1 (en) * 2010-04-16 2013-02-11 Methylgene Inc Inhibitors of protein tyrosine kinase activity
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
US8633317B2 (en) * 2010-06-09 2014-01-21 Abbvie Inc. Crystalline salts of thieno[3,2-c]pyridine kinase inhibitors with improved cpy safety profile
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
EA201300283A1 (ru) * 2010-08-27 2013-08-30 Мерк Патент Гмбх Производные фуропиридина
EP2616441B1 (en) * 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
BRPI1004176A2 (pt) * 2010-10-25 2015-08-11 Univ Rio De Janeiro Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CN111620861A (zh) * 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
WO1999024440A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
AU2001252463A1 (en) 2000-06-06 2001-12-17 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
JP2005527511A (ja) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2005009348A2 (en) 2003-06-25 2005-02-03 Ariad Pharmaceuticals, Inc. Substituted purine derivatives
CA2536321A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005052872A1 (en) * 2003-11-21 2005-06-09 Facil, Llc Financial transaction system and method
CA2553433A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
MX2007000631A (es) 2004-07-16 2007-03-30 Sunesis Pharmaceuticals Inc Tienopirimidinas utiles como inhibidores de aurora cinasa.
CA2573538C (en) 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
US7652009B2 (en) * 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JP2008537748A (ja) 2005-04-06 2008-09-25 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
JP5148499B2 (ja) 2005-05-20 2013-02-20 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
ES2473341T3 (es) * 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
US7298968B1 (en) * 2007-01-05 2007-11-20 Rheem Manufacturing Company Pumpless combination instantaneous/storage water heater system
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
PH12012502073A1 (en) * 2010-04-16 2013-02-11 Methylgene Inc Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
RU2010145459A (ru) 2012-05-20
ZA201005868B (en) 2011-08-31
AR079208A2 (es) 2012-01-04
CN102161663A (zh) 2011-08-24
CN102161663B (zh) 2014-03-19
BRPI0908573A2 (pt) 2012-12-25
CN102015723B (zh) 2014-07-30
ZA201007517B (en) 2012-01-25
CN102015723A (zh) 2011-04-13
US8729268B2 (en) 2014-05-20
EP2262815A1 (en) 2010-12-22
MX2010009729A (es) 2010-12-21
CA2717816A1 (en) 2009-09-11
CA2763168A1 (en) 2009-09-11
IL207946A0 (en) 2010-12-30
WO2009109035A1 (en) 2009-09-11
NZ588355A (en) 2012-03-30
RU2533827C2 (ru) 2014-11-20
KR20100137495A (ko) 2010-12-30
US8759522B2 (en) 2014-06-24
AU2009221583A2 (en) 2011-02-03
US20110077240A1 (en) 2011-03-31
IL208882A0 (en) 2011-07-31
TW200940549A (en) 2009-10-01
EP2262815A4 (en) 2012-04-11
AU2009221583A1 (en) 2009-09-11
SG182146A1 (en) 2012-07-30
US20140179632A1 (en) 2014-06-26
NZ589336A (en) 2011-12-22
TW201113288A (en) 2011-04-16
RU2498988C2 (ru) 2013-11-20
JP5661485B2 (ja) 2015-01-28
JP2011513339A (ja) 2011-04-28
EP2332536A1 (en) 2011-06-15
TWI438205B (zh) 2014-05-21
RU2010140668A (ru) 2012-04-10
JP2011105735A (ja) 2011-06-02
UA100262C2 (ru) 2012-12-10
AR070539A1 (es) 2010-04-14
US20110098293A1 (en) 2011-04-28
CO6290684A2 (es) 2011-06-20
AU2009221583B2 (en) 2013-06-20
KR20100132068A (ko) 2010-12-16
AU2010246540A1 (en) 2010-12-23
BRPI0923670A2 (pt) 2013-07-30
AU2010246540B2 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
UA100262C2 (ru) Ингибиторы активности протеинтирозинкиназы
MY157319A (en) Inhibitors of protein tyrosine kinase activity
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
WO2007149427A3 (en) Tyrosine kinase inhibitors
PH12020551208A1 (en) Compounds for the treatment of kinase-dependent disorders
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2012037155A3 (en) Tyrosine kinase inhibitors
SI1896421T1 (sl) Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met
NO20090608L (no) Tyrosinkinaseinhibitorer
MY155621A (en) Axl antibodies
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
JO3346B1 (ar) مواد مضادة C5aR
ZA200906264B (en) Aminopyrimidines useful as inhibitors of protein kinases
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
TN2011000463A1 (en) Composition and methods for increasing muscle growth
MX2012002546A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
MX2011008602A (es) Metodos de tratamiento de condiciones relacionadas con el cabello.
WO2013063458A3 (en) Inhibiting g protein coupled receptor 6 kinase polypeptides